Business Description
Avidity Biosciences Inc
NAICS : 541714
SIC : 2834
10578 Science Center Drive, Suite 125, San Diego, CA, USA, 92121
Description
Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product candidate AOC 1001, is designed to treat a rare monogenic muscle disease.
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 33.69 | |||||
Equity-to-Asset | 0.89 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | -0.08 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | 13.21 | |||||
Beneish M-Score | -3.29 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 132.1 | |||||
3-Year EBITDA Growth Rate | -79.6 | |||||
3-Year EPS without NRI Growth Rate | -46.7 | |||||
3-Year FCF Growth Rate | -71.8 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 64.65 | |||||
9-Day RSI | 66.4 | |||||
14-Day RSI | 65.2 | |||||
6-1 Month Momentum % | 11.52 | |||||
12-1 Month Momentum % | -12.46 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 12 | |||||
Quick Ratio | 12 | |||||
Cash Ratio | 11.82 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -32.2 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -1860.12 | |||||
Net Margin % | -1849.49 | |||||
ROE % | -41.25 | |||||
ROA % | -37.2 | |||||
ROIC % | -643.13 | |||||
ROC (Joel Greenblatt) % | -1414.02 | |||||
ROCE % | -40.09 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 123.27 | |||||
PB Ratio | 2.89 | |||||
Price-to-Tangible-Book | 2.91 | |||||
EV-to-EBIT | -4.75 | |||||
EV-to-Forward-EBIT | -3.9 | |||||
EV-to-EBITDA | -4.79 | |||||
EV-to-Forward-EBITDA | -3.92 | |||||
EV-to-Revenue | 87.9 | |||||
EV-to-Forward-Revenue | 182.41 | |||||
EV-to-FCF | -6.09 | |||||
Price-to-Net-Current-Asset-Value | 3.06 | |||||
Price-to-Net-Cash | 3.12 | |||||
Earnings Yield (Greenblatt) % | -21.14 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:RNA
Executives
EMBED
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 7.988 | ||
EPS (TTM) ($) | -3.95 | ||
Beta | 0 | ||
Volatility % | 48.77 | ||
14-Day RSI | 65.2 | ||
14-Day ATR ($) | 1.284363 | ||
20-Day SMA ($) | 18.6565 | ||
12-1 Month Momentum % | -12.46 | ||
52-Week Range ($) | 10.89 - 29.25 | ||
Shares Outstanding (Mil) | 52.13 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Avidity Biosciences Inc Filings
Document | Form | Filing Date | ||
---|---|---|---|---|
No Filing Data |